Companies Dominating the Pediatric Cancer Treatment Drugs Landscape
- Bristol Myers Squibb Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Epizyme, Inc.
- Eisai Co., Ltd.
- Recordati Rare Diseases Inc.
- Merck & Co., Inc.
- Novartis AG
- Leadiant Biosciences
- EUSA Pharma, Inc.
- Jazz Pharmaceuticals plc
- Amgen Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Pediatric Cancer Treatment Drugs Market size is poised to witness lucrative growth rate during the forecast period i.e., between 2025-2037.
The market growth is driven by increasing occurrence of cancer among children, and rising prevalence of childhood obesity worldwide.
Asia Pacific industry is anticipated to account for largest revenue share by 2037, ascribed to increasing government investments to enhance the medical infrastructure, and rising awareness about different treatment options in pediatric oncology.
The major players in the market are Bristol Myers Squibb Company, Epizyme, Inc., Eisai Co., Ltd., Recordati Rare Diseases Inc., Merck & Co., Inc., and others.
